Affinity Capital Advisors’s Esperion Therapeutics ESPR Stock Holding History

Affinity Capital Advisors’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-10,000	Closed	-$31.5K	–	239
2026 Q2	$31.5K	Hold	10,000	–	–	﹤0.01%	201
2026 Q1	$27.4K	Hold	10,000	–	–	﹤0.01%	180
2025 Q4	$37K	Hold	10,000	–	–	0.01%	172
2025 Q3	$29K	Hold	10,000	–	–	﹤0.01%	152
2025 Q2	$9.84K	Hold	10,000	–	–	﹤0.01%	159
2025 Q1	$10.2K	Buy	+10,000	New	+$18.4K	﹤0.01%	154

Affinity Capital Advisors's ESPR Position: Q3 2026 in Review

Affinity Capital Advisors sold out of Esperion Therapeutics (ESPR) in Q3 2026, closing a stake of 10,000 shares — an estimated $31.5K sold.

Affinity Capital Advisors first reported a position in ESPR in Q1 2025 and held it in 6 quarters. The position peaked at $37K in Q4 2025. 0 funds tracked by Wall St. Rank hold ESPR as of Q3 2026.

Affinity Capital Advisors reported no remaining Esperion Therapeutics position as of Q3 2026 after selling out during the quarter.
Affinity Capital Advisors sold 10,000 Esperion Therapeutics shares in Q3 2026, an estimated $31.5K.
Affinity Capital Advisors first reported a position in Esperion Therapeutics in Q1 2025 and held it in 6 quarters.
Affinity Capital Advisors's Esperion Therapeutics position peaked at $37K in Q4 2025.
0 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2026.

Based on Affinity Capital Advisors's 13F filing for Q3 2026, filed 13 Oct 2026.